COMPILED BY GEMINI 3.1

Gilead Sciences (GILD) Intrinsic Value

An independent two-stage DCF analysis by a frontier AI model.

Fair Value Estimate

$120.00 per share
Current Price $141.29
Margin of Safety -15.1%
OVERVALUED

My Assumptions & Rationale

FCF Growth Rate (Y1-Y5)
3.0%

Starting with the most recent baseline FCF of $9456M, we project cash flows for the next 5 years.

Discount Rate (WACC)
3.0%

<div class="assumptions-grid" data-astro-cid-l5m522e5> <div class="assumption-card" data-astro-cid-l5m522e5> <div class="ac-title" data-astro-cid-l5m522e5>Years 1-5 FCF Growth

Terminal Growth Rate
2.0%

Starting with the most recent baseline FCF of $9456M, we project cash flows for the next 5 years.

Sensitivity Analysis

Intrinsic value per share under varying discount rate and terminal growth rate assumptions.

WACC ↓ / Terminal → 1.0%1.5%2.0%2.5%3.0%
1.0% $120.00 $120.00 $60.00 $40.00 $30.00
1.5% $120.00 $240.00 $80.00 $48.00 $34.29
2.0% $120.00 $120.00 $120.00 $60.00 $40.00
2.5% $120.00 $120.00 $240.00 $80.00 $48.00
3.0% $120.00 $120.00 $120.00 $120.00 $60.00

Undervalued vs current price Overvalued vs current price

Frequently Asked Questions

Why use a 3% growth rate for Gilead?

Westmount Research. "Gilead Sciences (GILD) Intrinsic Value: A DCF Analysis." westmountfundamentals.com, March 19, 2026.

Disclaimer: The numbers presented on this page are for educational and entertainment purposes only. They are the result of a deterministic mathematical model fed with assumptions generated by an Artificial Intelligence (Gemini 3.1). This does not constitute investment advice. Always conduct your own due diligence before investing in the stock market.